Tags

Type your tag names separated by a space and hit enter

Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Dement Geriatr Cogn Disord. 2009; 27(2):164-72.DG

Abstract

Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate receptors, approved for the treatment of moderate to severe Alzheimer's disease (AD). Available data suggest that, in addition to its benefits on cognition, function, and global status, memantine treatment may also help alleviate behavioral symptoms. This article provides an overview of the prevalence, assessment, and treatment of behavioral disturbances in AD, and summarizes current knowledge regarding the effects of memantine on the behavior of community-dwelling patients. We searched EMBASE and PubMed (January 1992 to October 2008) for reports on memantine trials that involved outpatients with moderate to severe AD. All previously unpublished data were obtained from Forest Laboratories, Inc. Behavioral outcomes were assessed in three completed, double-blind, placebo-controlled trials.Overall, patients who received memantine performed better on behavioral measures than those treated with placebo. Post-hoc analyses suggest that memantine treatment was associated with a reduced severity or emergence of specific symptoms, particularly agitation and aggression. Prospective, well-designed trials are warranted to evaluate the efficacy of memantine in patients with significant behavioral symptoms.

Authors+Show Affiliations

Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO 63104, USA. grossbgt@slu.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Review

Language

eng

PubMed ID

19194105

Citation

Grossberg, George T., et al. "Memantine Therapy of Behavioral Symptoms in Community-dwelling Patients With Moderate to Severe Alzheimer's Disease." Dementia and Geriatric Cognitive Disorders, vol. 27, no. 2, 2009, pp. 164-72.
Grossberg GT, Pejović V, Miller ML, et al. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27(2):164-72.
Grossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009). Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 27(2), 164-72. https://doi.org/10.1159/000200013
Grossberg GT, et al. Memantine Therapy of Behavioral Symptoms in Community-dwelling Patients With Moderate to Severe Alzheimer's Disease. Dement Geriatr Cogn Disord. 2009;27(2):164-72. PubMed PMID: 19194105.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. AU - Grossberg,George T, AU - Pejović,Vojislav, AU - Miller,Michael L, AU - Graham,Stephen M, Y1 - 2009/02/05/ PY - 2008/12/16/accepted PY - 2009/2/6/entrez PY - 2009/2/6/pubmed PY - 2009/5/29/medline SP - 164 EP - 72 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 27 IS - 2 N2 - Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate receptors, approved for the treatment of moderate to severe Alzheimer's disease (AD). Available data suggest that, in addition to its benefits on cognition, function, and global status, memantine treatment may also help alleviate behavioral symptoms. This article provides an overview of the prevalence, assessment, and treatment of behavioral disturbances in AD, and summarizes current knowledge regarding the effects of memantine on the behavior of community-dwelling patients. We searched EMBASE and PubMed (January 1992 to October 2008) for reports on memantine trials that involved outpatients with moderate to severe AD. All previously unpublished data were obtained from Forest Laboratories, Inc. Behavioral outcomes were assessed in three completed, double-blind, placebo-controlled trials.Overall, patients who received memantine performed better on behavioral measures than those treated with placebo. Post-hoc analyses suggest that memantine treatment was associated with a reduced severity or emergence of specific symptoms, particularly agitation and aggression. Prospective, well-designed trials are warranted to evaluate the efficacy of memantine in patients with significant behavioral symptoms. SN - 1421-9824 UR - https://www.unboundmedicine.com/medline/citation/19194105/Memantine_therapy_of_behavioral_symptoms_in_community_dwelling_patients_with_moderate_to_severe_Alzheimer's_disease_ DB - PRIME DP - Unbound Medicine ER -